Cat. No.: HY-N6958

2-O-β-D-Glucopyranosyl-L-ascorbic acid

(Synonyms: AA-2βG)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

2-O-β-D-Glucopyranosyl-L-ascorbic acid (AA-2βG) is an orally active vitamin C derivative. 2-O-β-D-Glucopyranosyl-L-ascorbic acid exhibits multiple activities including antioxidant, anti-tumor and immunomodulatory effects. 2-O-β-D-Glucopyranosyl-L-ascorbic acid mediates tumor cell apoptosis, induces cell cycle arrest, scavenges free radicals and eliminates oxidative stress. 2-O-β-D-Glucopyranosyl-L-ascorbic acid can be used in studies related to cancer, inflammation and immunity.

For research use only. We do not sell to patients.

Purity: 95.0%
CAS No.: 562043-82-7
Formula: C₁₂H₁₈O₁₁
Molecular Weight:338.26

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

2-O-β-D-Glucopyranosyl-L-ascorbic acid Chemical Structure

CAS No.: 562043-82-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All HSP Isoforms :

All Heme Oxygenase (HO) Isoforms :

HO-1
HO-2

In Vitro

2-O-β-D-Glucopyranosyl-L-ascorbic acid (1.0-5.0 mM; 24-72 h) selectively induces cytotoxicity and antiproliferative effects in a time- and dose-dependent manner in Hela, HS-746T and Colo-320 cancer cells^[1].
2-O-β-D-Glucopyranosyl-L-ascorbic acid (3.0 mM; 24-72 h) induces dose- and time-dependent apoptotic morphological changes in Hela cells, including chromatin condensation, membrane blebbing, and apoptotic body formation^[1].
2-O-β-D-Glucopyranosyl-L-ascorbic acid (0.001-1.0 mM; 24-48 h) induces time- and dose-dependent G0/G1 cell cycle arrest in Hela cells^[1].
2-O-β-D-Glucopyranosyl-L-ascorbic acid (5.0 mM; 24 h) downregulates the protein expression levels of vinculin, mitofilin, heat shock protein 60, α-tubulin, heterogeneous nuclear ribonucleoprotein H1, GAPDH, and c-Jun/AP-1, while it upregulates the protein expression level of p53^[1].
2-O-β-D-Glucopyranosyl-L-ascorbic acid (3.1-12.5 μM; 1 h) significantly inhibits hydrogen peroxide-induced production of ROS and superoxide anions, and restores mitochondrial transmembrane potential in mouse macrophage RAW264.7 cells^[2].
2-O-β-D-Glucopyranosyl-L-ascorbic acid (3.1-12.5 μM; 4 h) restores intracellular GSH levels, reduces GSSG levels, and increases the GSH/GSSG ratio in hydrogen peroxide-treated mouse RAW264.7 macrophages^[2].
2-O-β-D-Glucopyranosyl-L-ascorbic acid (3.1-12.5 μM; 4 h) restores the activities of superoxide dismutase and catalase in hydrogen peroxide-treated murine macrophage RAW264.7 cells^[2].
2-O-β-D-Glucopyranosyl-L-ascorbic acid (3.1-12.5 μM; 4 h) significantly reduces the release of LDH and TNF-α in hydrogen peroxide-induced mouse macrophage RAW264.7 cells^[2].
2-O-β-D-Glucopyranosyl-L-ascorbic acid (12.5 μM; 4 h pretreatment) downregulates Keap-1 expression and upregulates the expressions of Nrf2 and HO-1 in hydrogen peroxide-treated mouse macrophage RAW264.7 cells^[2].
2-O-β-D-Glucopyranosyl-L-ascorbic acid (12.5 μM; 4 h) promotes the nuclear translocation of Nrf2 in hydrogen peroxide-treated mouse macrophage RAW264.7 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

human cervix adenocarcinoma Hela cells, human gastric carcinoma HS-746T cells, human colorectal adenocarcinoma Colo-320 cells, human liver cancer Bel-7402 cells, human primary vascular endothelial VEC cells
Concentration:

1.0 mM, 2.0 mM, 3.0 mM, 4.0 mM, 5.0 mM
Incubation Time:

24 h, 48 h, 72 h
Result:

Induced cytotoxicity and antiproliferative effects in a cell type-, time-, and dose-dependent manner.
Caused 90% cell death in Hela cells treated with 5.0 mM for 72 h.
Reduced cell viability significantly in HS-746T and Colo-320 cells, with greater effects at higher concentrations and longer incubation times.
Showed moderate inhibition or slight promotion of cell viability in Bel-7402 cells and VEC cells.

Cell Cycle Analysis^[1]

Cell Line:

human cervix adenocarcinoma Hela cells
Concentration:

0.001 mM, 0.01 mM, 0.1 mM, 1.0 mM
Incubation Time:

24 h, 36 h, 48 h
Result:

Increased G0/G1 phase cell fraction and decreased S phase cell fraction in a time- and dose-dependent manner, indicating G0/G1 phase cell cycle arrest.
Resulted in 58.58% G0/G1 and 31.22% S phase cells with 0.001 mM treatment for 48 h.
Caused 60.95% G0/G1 and 26.72% S phase cells with 0.01 mM treatment for 48 h.
Induced 72.02% G0/G1 and 22.85% S phase cells with 0.1 mM treatment for 48 h.
Led to 85.16% G0/G1 and 11.16% S phase cells with 1.0 mM treatment for 48 h.
Raised G0/G1 fraction to 74.30% at 24 h, 80.69% at 36 h, and 85.16% at 48 h, while decreasing S phase fraction to 21.0% at 24 h, 14.27% at 36 h, and 11.16% at 48 h with 1.0 mM treatment.

Western Blot Analysis^[2]

Cell Line:

hydrogen peroxide (H₂O₂)-treated murine macrophage RAW264.7 cells
Concentration:

12.5 μM
Incubation Time:

4 h (pretreatment prior to 6 h H₂O₂ stimulation)
Result:

Downregulated H₂O₂-induced Keap-1 expression, and significantly reversed H₂O₂-suppressed Nrf2 and HO-1 expression levels, with statistically significant effects (p < 0.01) observed for all three proteins relative to H₂O₂-only treatment.

Immunofluorescence^[2]

Cell Line:

hydrogen peroxide (H₂O₂)-treated murine macrophage RAW264.7 cells
Concentration:

12.5 μM
Incubation Time:

4 h (pretreatment prior to 6 h H₂O₂ stimulation)
Result:

Induced nuclear translocation of Nrf2 following H₂O₂ stimulation, with increased Nrf2 fluorescence observed in the nuclear compartment relative to H₂O₂-only treatment.

In Vivo

2-O-β-D-Glucopyranosyl-L-ascorbic acid (100 mg/kg; i.g.; 32 days) exerts significant immunomodulatory activity in cyclophosphamide (HY-17420)-induced immunosuppressed BALB/c mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c treated Cyclophosphamide (HY-17420) (5-week-old, 16 ± 1.0 g)^[3]
Dosage:

100 mg/kg BW/day
Administration:

intragastric gavage; daily; 32 consecutive days
Result:

Significantly reversed cyclophosphamide-induced body weight loss, colon length reduction, and decreases in thymus and spleen indexes.
Significantly reversed cyclophosphamide-induced increases in neutrophil and monocyte percentages and decrease in lymphocyte percentage, with no significant effect on eosinophil percentage.
Significantly reversed cyclophosphamide-induced down-regulation of TNF-α, up-regulation of TGF-β1, and decrease in IgA levels; no significant effect on IL-10 levels.
Significantly reversed cyclophosphamide-induced decreases in hepatic GSH, CAT, and SOD levels and increase in ALT level; no significant effect on hepatic MDA level).
Prevented cyclophosphamide-induced histopathological damage to jejunum, colon, and liver tissue, maintaining intact villi structure and preventing liver focal solidification necrosis and vacuolar degeneration.
Significantly reversed cyclophosphamide-induced reductions in cecal i-butyric and i-valeric acid concentrations.
Reversed cyclophosphamide-induced increases in Epsilonbacteraeota and Proteobacteria relative abundances and decreases in Patescibacteria and Tenericutes relative abundances in colonic microbiota; reversed cyclophosphamide-induced changes in relative abundances of 13 bacterial families; significantly altered 61 colonic microbial functional modules compared to the cyclophosphamide-only group, including enriching amino acid metabolism/synthesis pathways and depleting disease-related pathways.
Significantly increased Bacteroidetes relative abundance, decreased Firmicutes relative abundance, and reversed cyclophosphamide-induced increase in Proteobacteria relative abundance in small-intestinal microbiota; significantly increased Muribaculaceae relative abundance and decreased Desulfovibrionaceae and Paenibacillaceae relative abundances compared to the cyclophosphamide-only group; significantly altered 119 small-intestinal microbial functional modules compared to the cyclophosphamide-only group, including enriching DNA replication/transcription/translation pathways, amino acid biosynthesis, and energy metabolism pathways, and depleting disease-related pathways.

Chemical Information

CAS No. 562043-82-7
Appearance Solid
Molecular Weight 338.26
Formula C₁₂H₁₈O₁₁
Color White to light yellow
SMILES

OC([C@H](O1)[C@H](CO)O)=C(O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)C1=O
Synonyms

AA-2βG
Structure Classification
- Saccharides
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Food Chem

Discovery of novel ascorbic acid derivatives and other metabolites in fruit of Rosa roxburghii Tratt through untargeted metabolomics and feature-based molecular networking. [Abstract]

2023 Mar 30;405(Pt A):134807. PMID: 36370576

Solvent & Solubility

In Vitro:

H₂O : ≥ 250 mg/mL (739.08 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9563 mL

14.7815 mL

29.5631 mL

5 mM

0.5913 mL

2.9563 mL

5.9126 mL

10 mM

0.2956 mL

1.4782 mL

2.9563 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (295.63 mM); Clear solution; Need ultrasonic

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (292 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang Z, et al. Selective suppression of cervical cancer Hela cells by 2-O-β-D-glucopyranosyl-L-ascorbic acid isolated from the fruit of Lycium barbarum L. Cell Biol Toxicol. 2011;27(2):107-121. [Content Brief]

[2]. Wang SF, et al. 2-O-β-d-glucopyranosyl-_l-ascorbic acid, a novel vitamin C derivative from Lycium barbarum, prevents oxidative stress. Redox Biol. 2019;24:101173. [Content Brief]

[3]. Huang K, et al. Ascorbic Acid Derivative 2-O-β-d-Glucopyranosyl-l-Ascorbic Acid from the Fruit of Lycium barbarum Modulates Microbiota in the Small Intestine and Colon and Exerts an Immunomodulatory Effect on Cyclophosphamide-Treated BALB/c Mice. J Agric Food Chem. 2020 Oct 7;68(40):11128-11143. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	2.9563 mL	14.7815 mL	29.5631 mL	73.9076 mL
	5 mM	0.5913 mL	2.9563 mL	5.9126 mL	14.7815 mL
	10 mM	0.2956 mL	1.4782 mL	2.9563 mL	7.3908 mL
	15 mM	0.1971 mL	0.9854 mL	1.9709 mL	4.9272 mL
	20 mM	0.1478 mL	0.7391 mL	1.4782 mL	3.6954 mL
	25 mM	0.1183 mL	0.5913 mL	1.1825 mL	2.9563 mL
	30 mM	0.0985 mL	0.4927 mL	0.9854 mL	2.4636 mL
	40 mM	0.0739 mL	0.3695 mL	0.7391 mL	1.8477 mL
	50 mM	0.0591 mL	0.2956 mL	0.5913 mL	1.4782 mL
	60 mM	0.0493 mL	0.2464 mL	0.4927 mL	1.2318 mL
	80 mM	0.0370 mL	0.1848 mL	0.3695 mL	0.9238 mL
	100 mM	0.0296 mL	0.1478 mL	0.2956 mL	0.7391 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

2-O-β-D-Glucopyranosyl-L-ascorbic acid

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

2-O-β-D-Glucopyranosyl-L-ascorbic acid

Bioactive Compound Library Max

Bioactive Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Transcription Factor-Targeted Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) 2-O-β-D-Glucopyranosyl-L-ascorbic acid

All HSP Isoforms

All Heme Oxygenase (HO) Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

2-O-β-D-Glucopyranosyl-L-ascorbic acid Related Classifications

HY-N6958 Related Classifications